Waters (WAT) Stock Rating Lowered by Goldman Sachs Group

Goldman Sachs Group downgraded shares of Waters (NYSE:WAT) from a neutral rating to a sell rating in a report published on Friday, MarketBeat Ratings reports. They currently have $180.00 price objective on the medical instruments supplier’s stock, down from their previous price objective of $185.00.

Several other research analysts have also weighed in on the stock. Leerink Swann lowered shares of Waters from an outperform rating to a market perform rating in a research note on Monday, October 8th. Morgan Stanley upped their price objective on shares of Waters from $204.00 to $211.00 and gave the company an equal weight rating in a research note on Wednesday, October 10th. JPMorgan Chase & Co. dropped their price objective on shares of Waters from $200.00 to $185.00 and set a neutral rating on the stock in a research note on Wednesday, October 24th. UBS Group dropped their price objective on shares of Waters from $210.00 to $200.00 and set a neutral rating on the stock in a research note on Wednesday, October 24th. Finally, Barclays dropped their price objective on shares of Waters from $200.00 to $190.00 and set an equal weight rating on the stock in a research note on Wednesday, October 24th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $205.07.

Shares of WAT stock traded down $4.91 during trading hours on Friday, reaching $198.58. 1,044,088 shares of the stock traded hands, compared to its average volume of 481,979. Waters has a 1-year low of $167.93 and a 1-year high of $220.20. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.63 and a quick ratio of 5.93. The firm has a market capitalization of $15.41 billion, a P/E ratio of 26.51, a P/E/G ratio of 2.44 and a beta of 0.94.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, October 23rd. The medical instruments supplier reported $1.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.90 by $0.02. The business had revenue of $578.02 million for the quarter, compared to analyst estimates of $587.43 million. Waters had a net margin of 2.32% and a return on equity of 30.68%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.77 earnings per share. Sell-side analysts predict that Waters will post 8.05 EPS for the current fiscal year.

In other Waters news, Director Thomas P. Salice sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 31st. The shares were sold at an average price of $192.00, for a total value of $672,000.00. Following the completion of the sale, the director now directly owns 20,911 shares of the company’s stock, valued at $4,014,912. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher A. Kuebler sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $199.67, for a total transaction of $1,597,360.00. Following the completion of the sale, the director now directly owns 18,911 shares of the company’s stock, valued at $3,775,959.37. The disclosure for this sale can be found here. Insiders own 0.98% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Captrust Financial Advisors bought a new stake in Waters in the third quarter worth approximately $107,000. Fort L.P. bought a new stake in shares of Waters during the 2nd quarter worth $118,000. Checchi Capital Advisers LLC bought a new stake in shares of Waters during the 3rd quarter worth $201,000. First Hawaiian Bank bought a new stake in shares of Waters during the 3rd quarter worth $208,000. Finally, Mission Wealth Management LP bought a new stake in shares of Waters during the 3rd quarter worth $208,000. 99.26% of the stock is owned by institutional investors.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Further Reading: Inflation

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit